Please login to the form below
COVID treatments
This page shows the latest COVID treatments news and features for those working in and with pharma, biotech and healthcare.
NICE publishes final draft guidance recommending three COVID-19 treatments
The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending three COVID-19 treatments for those at the highest risk of developing severe disease. ... It also said that it is currently developing a new
Latest news
-
Facts are stubborn things
regulators to punish doctors for spreading false information about COVID-19 vaccinations and treatments. ... The first undeniable policy and public health learning from COVID-19 is that medicine has no absolutes.
-
AstraZeneca’s Evusheld not recommended by NICE for COVID-19 prevention
from vaccination against COVID-19 as most people, and who therefore continue to significantly modify their behaviour to avoid infection.”. ... In the same statement, the agency also outlined that it is currently developing a new review process to
-
World Health Organization releases latest set of COVID-19 guidelines
The World Health Organization (WHO) has updated its COVID-19 guidelines on treatments, isolation periods and mask wearing. ... Included in the advice is a strong recommendation for the use of Pfizer’s Paxlovid (nirmatrelvir/ritonavir) in mild or
-
Pfizer and Clear Creek Bio partner on COVID-19 antiviral research programme
treatments against COVID-19. ... We look forward to working with Pfizer, a global leader in antiviral development, to advance a new class of oral antivirals for COVID-19.”.
-
National trial to rapidly find treatments for severe flu this winter launched in UK
REMAP-CAP will test multiple treatments at the same time in thousands of people. ... Multiple treatments will be tested in the trial, including the anti-viral treatments Tamiflu (oseltamivir) and baloxavir, as well as steroids and anti-inflammatory drugs
More from news
Approximately 1 fully matching, plus 73 partially matching documents found.
Latest Intelligence
-
Future-proofing pharma supply chains by improving inefficiencies in global health architecture
But as we have seen with COVID-19, the risks are very real. ... The international R&D effort to find experimental treatments and vaccines for COVID-19 has been laudable, given its novel nature and urgency.
-
Charting patient pathways with precision for better healthcare
Patients are at the heart of transforming pharma brands and they need to understand that these insights will enable companies to design and deliver drugs, approaches, support services and treatments that ... People were naturally reluctant to go to
-
The lessons learned from COVID-19’s impact on oncology trials
How COVID-19’s lasting legacy will reshape clinical cancer research. COVID-19 has dramatically impacted the overall management of clinical trials. ... Even more, sites that conduct clinical trials, like university hospital systems, have understandably
-
A new era for UK-Japanese scientific research relations
Most recently, Japanese firms have led research on plasma-based treatments for COVID-19. ... Not only does this provide a set of challenges for the Japanese government and health system, but for pharmaceutical companies trying to develop new and
-
A cultural shift in clinical research
The impact of the COVID-19 pandemic. For the scientific community, 2020 was a pivotal year. ... But while unprecedented feats were achieved in clinical research for COVID-19 treatments and vaccines, many other projects were halted and patient recruitment
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest from PMHub
-
Remote Patient Monitoring
The COVID-19 pandemic has brought into sharp focus the need to harness and leverage digital tools and technology for remote patient monitoring (RPM). ... 7. Furthermore, data can inform clinical research into drug discovery and disease prevention,
-
Challenges and opportunities during a changing environment for scientific communications – key themes from the ISMPP EU 2021 meeting
A third key theme focussed on misinformation and trust in the COVID-19 era. ... This was the topic of a poster by Nucleus Global, which discussed the role of scientific publications in driving public discussion around treatments of COVID-19 (). There was
-
The heavy toll of COVID-19 on cancer patients
During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. ... Several regulations surrounding clinical trials have been loosened during COVID-19, particularly in the US.
-
Medical research charities need our help – support is needed to continue funding life-saving research and improving lives
At a time where medical research is most needed, charities are facing unprecedented falls in income due to COVID-19. ... challenging and life-threatening diseases for which there are limited or no treatments available today.
-
September 2020: diversity and inclusion in clinical trials round-up
A new focus on recruiting ethnic minority patients for a major COVID-19 trial. ... It aims to find treatments for COVID-19 that are suitable for patients aged over 50, and that can be taken at home and therefore reduce the need for patients to
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
-
Technical Sales Representative
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- The speed of science and the pace of comms
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
- Improving cardiovascular disease care and awareness
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Locus Biosciences announces first patient treated in urinary tract infection trial
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
PMHub
BOLDSCIENCE
We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...
Latest intelligence
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
